Tag: cannabis
-
The real reason for XPhyto’s (XPHY.C) freaky gravity-defying chart
XPHY owns a German narcotic manufacturer called Vektor Pharma, another subsidiary called Bunker that has all the licenses to study cannabis as a medicine, and it has formed multiple partnerships with universities and research centers.
-
Canopy Growth Corp (WEED.T) to detonate another $800m in assets in bid to find balance sheet harmony
There’s no doubt a lot of people invest in a sector by just plopping their dough behind whichever company is the biggest, or the one they’ve heard of most, without actually looking at the fundamentals of that company. This is as much a cemented belief for me as the belief that songs that get played…
-
European office supplies manufacturer takes Wayland Group (WAYL.C) weed grow for $12.3m
The Wayland Group (WAYL.C) announced Thursday Austria-based Ring Holding International AG will purchase their Maricann assets, which essentially make up their entire business, for the bargain price of $12.3 million as part of ongoing bankruptcy proceedings. The purchaser of the Maricann assets is a family office with a core focus on the manufacturing of lever…
-
Aurora (ACB.NYSE) rolls back, Gaia Grow (GAIA.V) rolls on
“The simple fact of the matter is ACB is getting around a THIRD of their product returned in real dollar terms,” wrote Equity Guru’s Chris Parry two months ago, “That means they either REALLY suck at growing weed, or they really sucked at figuring out what the market was going to look like when planning…
-
The Good, the Bad & the Ugly; Trulieve Cannabis (TRUL.C), KushCo Holdings (KSHB.OTC) and Hexo (HEXO.NYSE) release financials
“Borrowing money and expanding hard in competition with MedMen (MMEN.C) is a two-edged sword,” explained Equity Guru’s Chris Parry, “In a strong market, you’re building far more value than you’re borrowing but, in a down market, you’re under extra pressure to keep things together when debts come due.”
-
Revive Therapeutics (RVV.C) warned about overhype, but up 26% on clinical trial news
Oddball pharmaceutical player Revive Therapeutics (RVV.C) found itself on the back end of a warning by the BCSC this week, that certain German players in the smallcap promotion space had over-hyped the mushroom/cannabis/biotech deal and promised big wins inappropriately for anyone who invested. As a marketing partner of Revive, I got a few panicky texts…
-
Nextleaf (OILS.C) cuts a deal with an Ontario cannabis grower
OIL’s CEO, Paul Pedersen, believes the key to a strong sustainable cannabis extraction business is innovative technology protected by international patents.
-
iAnthus (IAN.C) defaults on debenture payments – but is that a weakness or a tactic?
Long time readers know, a year or two back, we wrote a lot about a US multi-state operator (MSO) in the cannabis dispensary space, iAnthus (IAN.C). We liked the company as it accelerated its dispensary acquisition program but stopped coverage in early 2019, with the shareprice in the $5 range, as it began to overpay…
-
James A. Wagner Cultivation (JWCA) goes into creditor protection, financier jumps 50%
It’s never been clearer that many Canadian cannabis companies were built, from the outset, poorly. As the economy creaks and groans and every sector takes a hit from COVID-19 effects, cannabis should be an exception to the rule because, if my circle is any indication, a lot of folks are at home, bored, and getting…
-
1933 Industries (TGIF.C) scrambles to keep up with increased Nevada cannabis demand
Last week, Nevada Governor Steve Sisolak allowed the shops to continue at-home deliveries because marijuana is considered an “essential business”, reported The Reno Gazette, “Much like the grocery stores trying to fill orders for rice and potatoes, cannabis retailers cannot fill marijuana delivery orders fast enough.”